Citations

Mayo Clinic

Showing 10 of 108599 citations.

Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci
Glubb, Dylan M. , Group, the AGO Study, Johnatty, Sharon E. , Quinn, Michael C. , O’Mara, Tracy A. , Gao, Bo , Fasching, Peter A. , Beckmann, Matthias W. , Lambrechts, Diether , Vergote, Ignace , Beeghly‐Fadiel, Alicia, Benı́tez, Javier , García, María J. , Goodman, Marc T. , Thompson, Pamela J., Dörk, Thilo , Modungo, Francesmary, Moysich, Kirsten B. , Heitz, Florian , Pfisterer, Jacobus , Hillemanns, Peter , Lester, Jenny, Goode, Ellen L. , Cunningham, Julie M. , McCauley, Bryan M. , Jensen, Allan , Schildkraut, Joellen M. , Terry, Kathryn L. , Salvesen, Helga B., Webb, Penny M., Grant, Peter J. , Moffitt, Melissa , Høgdall, Claus , Paul, James, Bernardini, Marcus Q. , Tone, Alicia , Huntsman, David, Woo, Michelle, Group, AOCS, DeFazio, Anna , Kennedy, Catherine J. , MacGregor, Stuart , Chenevix‐Trench, Georgia , Webb, Penelope M. , Bowtell, David D.L. , Lambrechts, Diether , Winham, Stacey J. , Fazio, Anna de , Group, the AGO Study, Tyrer, Jonathan P. , Edwards, Digna R. Velez , Beeghly‐Fadiel, Alicia , Dürst, Matthias , Bois, Andreas du , Karlan, Beth Y. , Larson, Melissa C. , Kjær, Susanne K. , Berchuck, Andrew , Cramer, Daniel W. , Bjørge, Line , Webb, Penny M., Pejovic, Tanja B. , Høgdall, Estrid , Glasspool, Rosalind , Group, AOCS, Pharoah, Paul D.P. , Dörk, Thilo , Lambrechts, Diether , Webb, Penelope M , Hillemanns, Peter , Jensen, Allan , Moysich, Kirsten , Kennedy, Catherine J , O'Mara, Tracy A , Heitz, Florian , Lambrechts, Diether , Quinn, Michael C J , MacGregor, Stuart , Benitez, Javier , Chenevix-Trench, Georgia , Høgdall, Claus K , Bowtell, David D , Goodman, Marc T

Oncotarget | June 15, 2017 | Volume: 8 | Issue: 39 | Pages: 64670-64684

10.18632/oncotarget.18501 | PMID 29029385 Get It

Thoracic Imaging After Bariatric Surgery
Sonavane, Sushilkumar K. , Sanyal, Rupan , Singh, Satinder P. , Menias, Christine O. , Galgano, Samuel J, Galgano, Samuel Joseph , Bhalla, Sanjeev

Journal of Thoracic Imaging | June 15, 2017 | Volume: 32 | Issue: 5 | Pages: W45-W53

10.1097/rti.0000000000000286 | PMID 28622165 Get It

Obesity and its association with long-term health problems constitutes one of the major challenges in medicine. Though diet regulation and exercise are the primary treatment strategies, surgery is the most reliable long-term solution. Although bariatric surgical complications continue to decline, prompt recognition is essential to optimize patient outcomes. Despite their relative rarity, it is important to recognize thoracic complications, as several of these can result in severe morbidity and mortality. This article describes common bariatric surgical procedures performed, their expected postoperative appearances, and intrathoracic complications.
Extraskeletal Osteosarcoma
Fritchie, Karen , Haddox, Candace L. , Rose, Peter S. , Arndt, Carola A.S., Marks, Randolph S., Okuno, Scott H. , Paludo, Jonas , Galanis, Evanthia , Robinson, Steven I. , Haddox, Candace L

American Journal of Clinical Oncology | June 15, 2017 | Volume: 41 | Issue: 9 | Pages: 832-837

10.1097/coc.0000000000000397 | PMID 28622153 Get It

Objectives: Extraskeletal osteosarcoma (EO) is a malignant neoplasm that produces osteoid, bone, and chondroid material without direct attachment to bone or periosteum. Surgical resection is the mainstay of treatment; the role of chemotherapy is not well defined. Therefore, we evaluated the impact of chemotherapy in the survival of patients with EO. Methods: All EO patients seen at Mayo Clinic between 1990 and 2014 were assessed. Forty-three patients were included after all archived pathology slides were reviewed to confirm the diagnosis of EO. Results: Of 43 patients, 37 patients had localized disease and 6 patients had metastatic disease at diagnosis. Chemotherapy was used in 73% and 75% of patients, respectively. Chemotherapy was predominantly anthracycline based, and included platinum in 22 patients (84%). Median overall survival (OS) and progression-free survival (PFS) were 50 months (95% confidence interval, 25-99), and 21 months (95% confidence interval, 13-not reached), respectively. There was a trend towards longer OS and PFS in patients who received chemotherapy. Those who received platinum-based therapy had remarkably prolonged OS (median, 182 vs. 18 mo; 5-year, 61% vs. 0%; P=0.01) and PFS (median, not reached vs. 10 mo; 5-year, 56% vs. 0%; P=0.005). Baseline characteristics were similar in the platinum and nonplatinum group. In patients who received chemotherapy, relapse/recurrence rate was lower in the platinum-based group (41%) as opposed to the nonplatinum-based group (100%; P=0.02). In the neoadjuvant setting, the overall response rate of platinum-containing regimens was 27%. Conclusions: Our results suggest a clinical benefit when platinum-based chemotherapy is incorporated in the management of patients with EO. We plan to validate this further with an expanded multicenter analysis.
Effect of position, time in the season, and playing surface on Achilles tendon ruptures in NFL games: a 2009-10 to 2016-17 review
Krill, Michael K. , Borchers, James, Hoffman, Joshua, Krill, Matthew L., Hewett, Timothy E.

The Physician and Sportsmedicine | June 15, 2017 | Volume: 45 | Issue: 3 | Pages: 259-264

10.1080/00913847.2017.1343652 | PMID 28617627 Get It

Improved localization, spectral quality, and repeatability with advanced MRS methodology in the clinical setting
Deelchand, Dinesh K. , Kantarci, Kejal , Öz, Gülin , Öz, Gülin , Kantarci, Kejal , Deelchand, Dinesh K

Magnetic Resonance in Medicine | June 15, 2017 | Volume: 79 | Issue: 3 | Pages: 1241-1250

10.1002/mrm.26788 | PMID 28618085 Get It

PurposeTo investigate the utility of an advanced magnetic resonance spectroscopy (MRS) protocol in the clinical setting, and to compare the localization accuracy, spectral quality, and quantification repeatability between this advanced and the conventional vendor‐provided MRS protocol on a clinical 3T platform.MethodsProton spectra were measured from the posterior cingulate cortices in 30 healthy elderly subjects by clinical MR technologists using a vendor‐provided (point resolved spectroscopy with advanced 3D gradient‐echo B0 shimming) and an advanced (semi‐LASER with FAST(EST)MAP shimming) protocol, in random order. Spectra were quantified with LCModel using standard pipelines for the clinical and research settings, respectively.ResultsThe advanced protocol outperformed the vendor‐provided protocol in localization accuracy (chemical‐shift‐displacement error: 2.0%/ppm, semi‐LASER versus 11.6%/ppm, point resolved spectroscopy), spectral quality (water linewidth: 6.1 ± 1.8 Hz, FAST(EST)MAP versus 10.5 ± 3.7 Hz, 3D gradient echo; P < 7e‐6; residual water: 0.08 ± 0.12%, VAPOR versus 0.45 ± 0.50%, WET; P < 2e‐5) and within‐session repeatability of metabolite concentrations, particularly of low signal‐to‐noise ratio data with two to eight averages (test‐retest coefficients of variance of metabolite concentrations, P < 0.01). Concentrations of J‐coupled metabolites such as γ‐aminobutyric acid and glutamate were biased when using the default pipeline with simulated macromolecules.ConclusionsThe quality of MRS data can be improved using advanced acquisition and analysis protocols on standard 3T hardware in the clinical setting, which can facilitate robust applications in central nervous system diseases. Magn Reson Med 79:1241–1250, 2018. © 2017 International Society for Magnetic Resonance in Medicine.
Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study
Jian‐Yu, E , Lu, Shou‐En , Graber, Judith M. , Rotter, David , Zhang, Lanjing , Petersen, Gloria M. , Demissie, Kitaw , Lu‐Yao, Grace L. , Tan, Xiang-Lin, Lin, Yong , Tan, Xiang‐Lin

Cancer Epidemiology, Biomarkers & Prevention | June 15, 2017 | Volume: 26 | Issue: 8 | Pages: 1225-1232

10.1158/1055-9965.epi-17-0227 | PMID 28619830 Get It

Abstract Background: Published evidence indicates that individual use of metformin and statin is associated with reduced cancer mortality. However, their differential and joint effects on pancreatic cancer survival are inconclusive. Methods: We identified a large population-based cohort of 12,572 patients ages 65 years or older with primary pancreatic ductal adenocarcinoma (PDAC) diagnosed between 2008 and 2011 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. Exposure to metformin and statins was ascertained from Medicare Prescription Drug Event files. Cox proportional hazards models with time-varying covariates adjusted for propensity scores were used to assess the association while controlling for potential confounders. Results: Of 12,572 PDAC patients, 950 (7.56%) had used metformin alone, 4,506 (35.84%) had used statin alone, and 2,445 (19.45%) were dual users. Statin use was significantly associated with improved overall survival [HR, 0.94; 95% confidence interval (CI), 0.90–0.98], and survival was more pronounced in postdiagnosis statin users (HR, 0.69; 95% CI, 0.56–0.86). Metformin use was not significantly associated with overall survival (HR, 1.01; 95% CI, 0.94–1.09). No beneficial effect was observed for dual users (HR, 1.00; 95% CI, 0.95–1.05). Conclusions: Our findings suggest potential benefits of statins on improving survival among elderly PDAC patients; further prospective studies are warranted to corroborate the putative benefit of statin therapy in pancreatic cancer. Impact: Although more studies are needed to confirm our findings, our data add to the body of evidence on potential anticancer effects of statins. Cancer Epidemiol Biomarkers Prev; 26(8); 1225–32. ©2017 AACR.
Patient Safety Interprofessional Training for Medical, Nursing, and Pharmacy Students
Gill, Anne C. , Cowart, Jennifer B. , Hatfield, Catherine L. , Stritto, Rita Ann Dello, Landrum, Peggy, Ismail, Nadia , Nelson, Elizabeth A., Teal, Cayla R. , Nelson, Elizabeth A.

MedEdPORTAL | June 15, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.10595 | PMID 30800797 Get It

Loss of FAM46C Promotes Cell Survival in Myeloma
Zhu, Yuan Xiao , Shi, Chang-Xin, Bruins, Laura A., Jedlowski, Patrick , Wang, Xuewei , Luo, Moulun , Ahmann, Jonathan M., Braggio, Esteban , Stewart, A. Keith, Kortüm, K. Martin , Braggio, Esteban

Cancer Research | June 15, 2017 | Volume: 77 | Issue: 16 | Pages: 4317-4327

10.1158/0008-5472.can-16-3011 | PMID 28619709 Get It

Abstract FAM46C is one of the most recurrently mutated genes in multiple myeloma; however its role in disease pathogenesis has not been determined. Here we demonstrate that wild-type (WT) FAM46C overexpression induces substantial cytotoxicity in multiple myeloma cells. In contrast, FAM46C mutations found in multiple myeloma patients abrogate this cytotoxicity, indicating a survival advantage conferred by the FAM46C mutant phenotype. WT FAM46C overexpression downregulated IRF4, CEBPB, and MYC and upregulated immunoglobulin (Ig) light chain and HSPA5/BIP. Furthermore, pathway analysis suggests that enforced FAM46C expression activated the unfolded protein response pathway and induced mitochondrial dysfunction. CRISPR-mediated depletion of endogenous FAM46C enhanced multiple myeloma cell growth, decreased Ig light chain and HSPA5/BIP expression, activated ERK and antiapoptotic signaling, and conferred relative resistance to dexamethasone and lenalidomide treatments. Genes altered in FAM46C-depleted cells were enriched for signaling pathways regulating estrogen, glucocorticoid, B-cell receptor signaling, and ATM signaling. Together these results implicate FAM46C in myeloma cell growth and survival and identify FAM46C mutation as a contributor to myeloma pathogenesis and disease progression via perturbation in plasma cell differentiation and endoplasmic reticulum homeostasis. Cancer Res; 77(16); 4317–27. ©2017 AACR.
Mutation in BRAF V600E: A Poor Prognostic Marker in Stage III Colon Cancers With Deficient MMR?—Reply
Shi, Qian , Sinicrope, Frank A. , Alberts, Steven R. , Shi, Qian

JAMA Oncology | June 15, 2017 | Volume: 3 | Issue: 9 | Pages: 1285

10.1001/jamaoncol.2017.1474 | PMID 28617912 Get It